Treatment Approach for Androgen Receptor–Indifferent Prostate Cancer

Video

This video covers the treatment approach for patients with androgen receptor–indifferent prostate cancer.

In this video, Ana Aparicio, MD, of the University of Texas MD Anderson Cancer Center, discusses the treatment approach for patients with androgen receptor (AR)-indifferent prostate cancer.

AR-indifferent prostate cancer can include patients with small-cell carcinoma or neuroendocrine tumors, which are often AR-negative, but often these are mixed with disease elements that do express the AR.

Recent data suggests these patients are more likely to response to platinum-based chemotherapy such as carboplatin.

Aparicio gave a presentation on this topic at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.